Determination of irinotecan, SN‐38 and SN‐38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients. Issue 1 (10th April 2017) - Atasilp, Chalirmporn
Abstract : Background: Irinotecan (CPT‐11) is chemotherapy used mainly in the metastatic colorectal cancer. The purpose of this study was to develop and validate the LC‐MS/MS for the simultaneous determination of CPT‐11, SN‐38, and SN‐38G. Methods: A 100 μL of plasma was prepared after protein precipitation and analyzed on a C18 column using 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile as mobile phases. The mass spectrometer worked with multiple reaction monitoring (MRM) in positive scan mode. The standard curves were linear on a concentration range of 5‐10 000 ng/mL for CPT‐11, 5‐1000 ng/mL for SN‐38, and 8‐1000 ng/mL for SN‐38G. Results: In this assay, the intra and interday precision consisted of ≤9.11% and ≤11.29% for CPT‐11, ≤8.70% and 8.31% for SN‐38, and ≤9.90 and 9.64% for SN‐38G. Conclusion: This method was successfully used to quantify CPT‐11, SN‐38, and SN‐38G and applied to a pharmacokinetic study.